300171.SZ
东富龙
SZSE · Healthcare · C 制造业 · CN
CNY 13.77
−4.57%Year over year
Reported trailing growth
- Revenue
- +3.3%
- EBITDA
- —
- EBIT
- +85.4%
- EPS
- +37.8%
- Free cash flow
- +181.6%
- Operating cash flow
- +6.8%
Forward estimates
Based on analyst estimates
- Revenue
- -44.8%
- EBITDA
- -9.8%
- EPS
- +14.0%
Three-year CAGR
- Revenue
- -1.5%
- EBITDA
- -26.3%
- EBIT
- -35.7%
- Net income
- -38.1%
- EPS
- -42.1%
- Free cash flow
- +20.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026